Who are FOLFIRI + cetuximab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FOLFOXIRI + Bevacizumab, modified FOLFOX6 + bevacizumab, Folfox with avastin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/folfiri-cetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

FOLFIRI + cetuximab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FOLFIRI + cetuximab (FOLFIRI + cetuximab) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination + monoclonal antibody. Area: Oncology.

marketed Chemotherapy combination + monoclonal antibody EGFR (epidermal growth factor receptor); DNA (via FOLFIRI) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

FOLFIRI + cetuximab (FOLFIRI + cetuximab) — Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). FOLFIRI chemotherapy combined with cetuximab targets rapidly dividing cancer cells and blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor growth.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FOLFIRI + cetuximab TARGET	FOLFIRI + cetuximab	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	marketed	Chemotherapy combination + monoclonal antibody	EGFR (epidermal growth factor receptor); DNA (via FOLFIRI)
FOLFOXIRI + Bevacizumab	FOLFOXIRI + Bevacizumab	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	phase 3	Chemotherapy combination + monoclonal antibody (anti-VEGF)	DNA (chemotherapy); VEGF (bevacizumab)
modified FOLFOX6 + bevacizumab	modified FOLFOX6 + bevacizumab	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	phase 3	Chemotherapy combination + monoclonal antibody	DNA (chemotherapy); VEGF (bevacizumab)
Folfox with avastin	Folfox with avastin	Sherief Abd-Elsalam	phase 3	Chemotherapy combination + monoclonal antibody (anti-VEGF)	DNA (chemotherapy); VEGF (bevacizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination + monoclonal antibody class)

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FOLFIRI + cetuximab — Competitive Intelligence Brief. https://druglandscape.com/ci/folfiri-cetuximab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing